Abstract: The present invention relates to identification and uses of biomarkers for neurodegenerative disease, including Alzheimer's disease, and the related diseases. More specifically, the present invention relates to the identification of protein biomarkers useful for the screening, diagnosis, and differentiation of Alzheimer's disease from Parkinson's disease, other neurodegenerative diseases, and normal controls, and in the monitoring of Alzheimer's disease severity and disease mechanisms in patients.

Abstract: The present invention relates to a Complement Factor H protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of a Complement Factor H protein, useful for the screening, diagnosis, and differentiation between neurodegenerative diseases.

Abstract: The present invention relates to an Apolipoprotein E3 protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of an Apolipoprotein E3 protein, useful for the screening, diagnosis, and differentiation of Parkinson's disease from Alzheimer's disease, other neurodegenerative diseases, and normal controls.

Abstract: The invention relates to an assay for discriminating between Alzheimer's disease (AD) patients, patients with AD-Like disorders that express symptoms like AD, and non-demented age-matched controls (Normal). The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having AD from Normals and patients having other AD-Like disorders.

Abstract: The invention relates to an assay for discriminating between amyotrophic lateral sclerosis (ALS) patients and patients with ALS-like disorders that express symptoms like ALS. The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having ALS from patients having other ALS-like disorders.

Abstract: The present invention is an assay for determining if a patient has a neuromuscular disease. The method comprises collecting a biological sample from a patient, separating the proteins present in the biological sample, quantitating a panel of proteins by proteomic techniques, analyzing the quantity of the protein panel using biostatistics, and determining whether or not the patient has a neuromuscular disease based on the statistical analysis of the results.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of a tripartite motif protein TRIM5 isoform gamma related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of the FK 506-binding protein 7, or prolylisomerase, as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an acetyl-LDL receptor related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an 2?-5?-oligoadenylate synthetase like protein (p59 OASL) related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention is a method for determining protein expression profiles in disease or an altered biological state. The method is based on the use of two-dimensional (2D) gel electrophoresis where the gel images are assigned two different colors. The gels are then compared by an overlay procedure that allows for identification and quantification of unique proteins by determining which colors are detected in the superimposed images and the density of those colors.

Abstract: The present invention is a biomarker for breast cancer, including early stage and precancerous conditions. Patients exhibiting reduced expression of acetyl-LDL receptor in a NAF sample collected from a breast that is below the 95% confidence limit of normals either have breast cancer are at high risk to develop breast cancer and should become the object of increased medical surveillance.

Abstract: The present invention provides methods and compositions for identifying cancer cells that are either sensitive or resistant to a particular anti-cancer therapy. Accordingly, the present invention allows for more accurate diagnosis, prognosis, and monitoring of a subject's condition. Furthermore, the ability to assess a subject's resistance or sensitivity to a particular treatment regimen will permit more informed treatment decisions to be made prior to beginning therapy. The present invention also overcomes deficiencies in the prior art concerning the treatment of cancers by providing methods and compositions for treating cancer and improving the effectiveness of other cancer therapies.

Abstract: The present invention is directed to overproduction of nitric oxide synthase (NOS) in a prokaryote. More particularly, the invention involves overexpression of functional neuronal NOS in a protease-deficient strain of Escherichia coli, utilizing a pCW vector under the control of the tac promotor. The invention further involves co-expression of the protein with folding agonists, or chaperonins. The enzyme produced is complete with heme and flavins, and may be activated by incubation with tetrahydrobiopterin. It may be isolated as a predominantly high spin heme protein that demonstrates spectral properties which are identical to those of nNOS isolated from human kidney 293 cells. The methods disclosed are contemplated to be useful in expressing large amounts of other nitric oxide synthases, as well as other proteins that are difficult to produce correctly folded in prokaryotes.